These findings demonstrate that iNK-CD64/16A cells are a potential “off-the-shelf” therapy to treat B cell lymphoma wherein overcoming antigen escape is critical. This evidence concerns the gene FCGR1A and B-cell non-Hodgkin lymphoma.